City of Champions Golf Tournament Approaches $1 Million for Prostate Cancer Research The fourth annual City of Champions Golf Tournament, led by Paul M. Wilson, CEO of NetReputation.com, and co-host…
Glaukos Highlights Expanding Innovation Portfolio at ASCRS 2026 Annual Meeting Glaukos Corporation, a leader in ophthalmic pharmaceuticals and medical technologies, has announced its participation in the 2026 American Society of…
Brightseed Unveils First Clinically Validated Enterprise AI Platform Backed by 10+ Years of Scientific Research Brightseed is redefining the future of health sciences innovation with the launch of its groundbreaking…
Carna Health Named to Fortune’s 2026 List of America’s Most Innovative Companies Carna Health, a pioneering digital health company focused on transforming kidney care and addressing cardio-kidney metabolic (CKM) conditions,…
Strategic Collaboration to Accelerate Human-Relevant Neuromuscular Testing Curi Bio and Battelle have announced a strategic collaboration aimed at transforming the field of neuromuscular pharmacology through the accelerated adoption of New…
GeneDx Study Shows Significant Healthcare Cost Savings and Improved Outcomes for Children After Genomic Testing A new real-world data study presented by GeneDx has revealed that genomic testing can dramatically…
United Therapeutics Corporation Shares TETON-2 Phase 3 Trial Findings in The New England Journal of Medicine United Therapeutics Corporation announced that the complete findings from its Phase 3 TETON-2 clinical…
Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program Precision BioSciences, Inc. a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for…
Eurofins Biomnis Launches New Clinical LC‑MS/MS Method for the Detection of Cereulide Toxin in Stool Samples Eurofins Biomnis, a leading European provider of specialised clinical diagnostics services, and part of…
TIXiMED Reports Promising Preclinical Results for Oral TIX100 in Preventing Weight Regain After GLP-1 Therapy TIXiMED a clinical-stage pharmaceutical company focused on developing innovative treatments for diabetes and metabolic diseases,…
Liberate Bio Secures Myeloid-Optimized CAR Design Licenses to Advance In Vivo CAR-M Programs Liberate Bio, Inc., a biotechnology company developing genetic medicines that deliver RNA therapies directly to immune cells,…
Response Pharmaceuticals Reports Positive 36-Week Phase 2 Data Supporting RDX-002 as a Long-Term Option in Post-GLP-1 Receptor Agonist Weight Management Response Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing therapies for…